Aurealis Therapeutics

Executive Summary

Aurealis Therapeutics is a Swiss-Finnish clinical-stage biotechnology company founded in 2018, focused on developing multi-target cell and gene therapies for complex, multifactorial diseases with high unmet medical needs. The company's core platform modulates the tissue microenvironment to address chronic wounds, cancer, and inflammatory diseases. Aurealis has advanced its lead program, AURE-001, into Phase 2 trials for chronic diabetic foot ulcers, leveraging a proprietary gene therapy approach that simultaneously targets multiple pathways involved in wound healing. The company has demonstrated promising preclinical and early clinical data, showing accelerated wound closure and improved tissue regeneration. In parallel, Aurealis is exploring additional indications and building a pipeline of candidates for oncology and inflammatory conditions. The company is privately held and has raised capital from investors including BioMedPartners and others, though specific financial details are not publicly disclosed. With its innovative platform and focus on high-need areas, Aurealis is positioned to address significant gaps in current treatment paradigms.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim data readout for AURE-001 in diabetic foot ulcers60% success
• Q1 2027Initiation of Phase 1/2 trial for AURE-002 in oncology50% success